New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

We are pleased to announce that Ernest Borjas will join Providence as Chief Financial Officer for Sonoma County, beginning Monday, Nov. 9.

In research, you refine until the kinks are out. Olivia takes the same approach in the kitchen.

Providence Women's Health opens in Walla Walla

With no family history of colon cancer and no symptoms, Julie Cropley thought at-home screening was OK. Now, she has cancer and two goals: survive colon cancer, and convince others to get screened.

After a breast cancer diagnosis and a difficult recovery, Grace Miller found strength, connection and a way to give back through Providence Holy Cross Medical Center’s Breast Cancer Support Group.

Thank you for participating in The Human Bean's annual Coffee for a Cure giveback day and supporting our cancer centers.

The work of our Providence Center for Health Care Ethics is always moving forward, as their unwavering commitment to caregivers, patients, and leaders remains rooted in our Mission.

Worried about your mammogram? Knowing what to expect can help you feel more comfortable and confident before this important screening.

Caregivers from Providence Hood River Memorial Hospital raised 173 pounds of food for a local food pantry during a recent volunteer activity.

Hospital earns top honors across cardiac, neurosciences, gastrointestinal, surgical, critical care and emergency medicine services.

Researchers evaluate whether adding pumitamig to chemotherapy can extend the lives of people with TNBC.

More than 20 presentations across 12 conferences highlight work in tumor immunology, molecular diagnostics, computational pathology and patient navigation.

Poorni Manohar, M.D., speaks with KATU's "AM Northwest" about new advances in screening and treatment that are providing patients with more personalized options and hope.

Providence Portland placed second in the world during the international Babies With Books read-a-thon. Meet the nurse who helped make the achievement possible.

The Staff Nurses Association (SNA) has announced that it will hold a two-day strike at Providence Santa Rosa Memorial Hospital. The strike is set to begin on Tuesday, October 27.

Providence Holy Cross Medical Center has launched a new outpatient pulmonary rehabilitation program, expanding access to specialized respiratory care for patients living with chronic lung conditions.

James Beckerman, M.D., offers helpful tips on KPTV for reducing heart disease risk with easy, consistent actions like short bouts of exercise, proper rest and nutrition.

Lori Tam, M.D., talks with KATU about how hormonal changes can affect heart health and what women can do to reduce their risk.

Mike Murray, M.D., talks with KATU about the changes in winter sport-related injuries and offers helpful strategies to prevent breaks and fractures.